Increased expression of the receptor for activation of NF-κB and decreased runt-related transcription factor 2 expression in bone of rats with streptozotocin-induced diabetes

International Journal of Molecular Medicine

Volumn 26, Issue 4, 2010, Pages 611-618

  Hie, Mamiko ^a   Tsukamoto, Ikuyo ^a  

^a NARA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Diabetes mellitus; Osteoblastogenesis; Osteoclastogenesis; Receptor for activation of nuclear factor B; Runt related transcription factor 2

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; BONE MORPHOGENETIC PROTEIN 2; C FMS PROTEIN; CALCIUM; CATHEPSIN K; COLLAGEN; COLONY STIMULATING FACTOR 1; DEOXYPYRIDINOLINE; HYDROXYPROLINE; INSULIN; MESSENGER RNA; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN C FOS; PROTEIN C JUN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR DLX5; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; EXCRETION; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RISK ASSESSMENT; STREPTOZOCIN DIABETES; TIBIA; UPREGULATION;

ANIMALS; BONE AND BONES; CELL DIFFERENTIATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; FEMALE; GENE EXPRESSION REGULATION; HUMANS; OSTEOBLASTS; OSTEOCLASTS; RATS; RATS, WISTAR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; TIBIA;

EID: 77957858845     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm-00000506     Document Type: Article

References (30)

1. Schwartz AV: Diabetes mellitus: Does it affect bone? Calcif Tissue Int 73: 515-519, 2003.
2. Kemink SA, Hermus AR, Swinkels LM, Lutterman JA and Smals AG: Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest 23: 295-303, 2000.
3. McCabe LR: Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem 102: 1343-1357, 2007.
4. Szkudelski T: The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50: 537-546, 2001.
5. Botolin S, Faugere MC, Malluche H, Orth M, Meyer R, and McCabe LR: Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice. Endocrinology 146: 3622-3631, 2005.
6. Herrero S, Calvo OM, Garcia-Moreno C, Martin E, San Roman JI, Martin M, Garcia-Talavera JR, Calvo JJ and del Pino-Montes J: Low bone density with normal bone turnover in ovariectomized and streptozotocin-induced diabetic rats. Calcif Tissue Int 62: 260-265, 1998. (Pubitemid 28127940)
7. Horcajada-Molteni MN, Chanteranne B, Lebecque P, Davicco MJ, Coxam V, Young A and Barlet JP: Amylin and bone metabolism in streptozotocin induced diabetic rats. J Bone Miner Res 16: 958-965, 2001.
8. Hie M, Shimono M, Fujii K and Tsukamoto I: Increased cathepsin K and tartrate-resistant acid phosphatase expression in bone of streptozotocin-induced diabetic rats. Bone 41: 1045-1050, 2007.
9. Hie M, Yamazaki M and Tsukamoto I: Curcumin suppresses increased bone resorption by inhibiting osteoclastogenesis in rats with streptozotocin-induced diabetes. Eur J Pharmacol 621: 1-9, 2009.
10. Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, Koga T, Martin TJ and Suda T: Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 87: 7260-7264, 1990. (Pubitemid 20325246)
11. Harada S and Rodan GA: Control of osteoblast function and regulation of bone mass. Nat Med 423: 349-355, 2003.
12. Asagiri M and Takayanagi H: The molecular understanding of osteoclast differentiation. Bone 40: 251-264, 2007.
13. Marie PJ: Transcription factors controlling osteoblastogenesis. Arch Biochem Biophys 473: 98-105, 2008.
14. Rosen V, Cox K and Hattersley G: Bone morphogenetic proteins. In: Principles of Bone Biology. Bilezikian JP, Raisz LG, Rodan GA (eds). Academic Press, San Diego, pp661-671, 1996.
15. Ducy P, Zhang R, Geoffroy V, Ridall AL and Karsenty G: Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89: 747-754, 1997.
16. Komori T: Regulation of osteoblast differentiation by transcription factors. J Cell Biochem 99: 1233-1239, 2006.
17. Miyama K, Yamada G, Yamamoto TS, Takagi C, Miyado K, Sakai M, Ueno N and Shibuya H: A BMP-inducible gene, dlx5, regulates osteoblast differentiation and mesoderm induction. Devel Biol 208: 123-133, 1999. (Pubitemid 29149452)
18. Lee MH, Kim YJ, Yoon WJ, Kim JI, Kim BG, Hwang YS, Wozney JM, Chi XZ, Bae SC, Choi KY, Cho JY, Choi JY and Ryoo HM: Dlx5 specifically regulates Runx2 type II expression by binding to homeodomain-response elements in the Runx2 distal promoter. J Biol Chem 280: 35579-35587, 2005.
19. Kim YJ, Lee MH, Wozney JM, Cho JY and Ryoo HM: Bone morphogenetic protein-2-induced alkaline phosphatase expression is stimulated by Dlx5 and repressed by Msx2. J Biol Chem 279: 50773-50780, 2004.
20. Bialek P, Kern B, Yang X, Schrock M, Sosic D, Hong N, Wu H, Yu K, Ornitz DM, Olson EN, Justice MJ and Karsenty G: A twist code determines the onset of osteoblast differentiation. Dev Cell 6: 423-435, 2004.
21. Goto A and Tsukamoto I: Increase in tartrate-resistant acid phosphatase of bone at the early stage of ascorbic acid deficiency in the ascorbate-requiring Osteogenic Disorder Shionogi (ODS) rat. Calcif Tissue Int 73: 180-185, 2003.
22. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM and Recker RR: Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2: 595-610, 1987.
23. Bjorgaas M, Haug E and Johnsen HJ: The urinary excretion of deoxypyridinium cross-links is higher in diabetic than in nondiabetic adolescents. Calcif Tissue Int 65: 121-124, 1999. (Pubitemid 29350648)
24. Manolagas SC: Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21: 115-137, 2000.
25. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ and Riggs BL: The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15: 2-12, 2000.
26. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT and Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345-357, 1999. (Pubitemid 30649812)
27. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM and Suda T: Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 190: 1741-1754, 1999.
28. Stein GS, Lian JB, van Wijnen AJ, Stein JL, Montecino M, Javed A, Zaidi SK, Young DW, Choi JY and Pockwinse SM: Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene 23: 4315-4329, 2004. (Pubitemid 38758597)
29. Ulsamer A, Ortuno MJ, Ruiz S, Susperregui AR, Osses N, Rosa JL and Ventura F: BMP-2 induces Osterix expression through up-regulation of Dlx5 and its phosphorylation by p38. J Biol Chem 283: 3816-3826, 2008.
30. Balla B, Kosa JP, Kiss J, Borsy A, Podani J, Takacs I, Lazary A, Nagy Z, Bacsi K, Speer G, Orosz L and Lakatos P: Different gene expression patterns in the bone tissue of aging postmenopausal osteoporotic and non-osteoporotic women. Calcif Tissue Int 82: 12-26, 2008.